Vanlev Heart Failure Role Strongest In High Systolic Blood Pressure Patients
Bristol-Myers Squibb Vanlev's potential role in the treatment of heart failure could be defined by an apparently stronger efficacy in patients with high systolic blood pressure, Bristol said
You may also be interested in...
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials